Pupiloscope, a Neuro-Critical Care Device, Enabling Quantitative, Real-Time, Pupillary Monitoring and Assessment of Patients with Neurotrauma and Head Injuries.

Descrizione del progetto

Un dispositivo innovativo per la valutazione oggettiva della pupilla

Un esame pupillare stima le dimensioni e la forma della pupilla a riposo, oltre alle sue risposte in seguito all’illuminazione dell’occhio. Questo esame si basa sul controllo neurologico della pupilla e viene utilizzato per diagnosticare una serie di condizioni, tra cui la lesione cerebrale traumatica a seguito di un trauma cranico. Il progetto PUPILOSCOPE, finanziato dall’UE, ha sviluppato una tecnologia innovativa che consente il monitoraggio quantitativo in tempo reale delle risposte pupillari. L’idea alla base del nuovo dispositivo è di superare la natura a rischio di errore umano degli esami pupillari convenzionali. È importante notare che non richiede alcuna formazione di esperti e offre uno strumento potente nella medicina d’urgenza, soprattutto per i pazienti con trauma cranico.

Obiettivo

An estimated 42 million people Worldwide suffer a Head Injury (2.5 million in the EU) that can lead to Mild or Traumatic Brain Injury (TBI). It is a major cause of death and disability, especially in young people, impacting victims and relatives, with significant costs to society, estimated at €33 Billion per annum in Europe alone.

Pre-Hospital and Emergency Care Neuro-Monitoring, including pupillary assessment, is critical in the processes of triage, management and medicating patients to prevent secondary injury to the brain. However, the current method of shining a light into a patient's eyes, in order to estimate pupillary response, is subjective and prone to human error.

The solution is Pupiloscope®, enabling Accurate, Real-time, Quantitative Pupillary Monitoring and Assessment for patients with potentially life threatening head injuries. Pupiloscope is a breakthrough technology that will positively impact clinical pathways as well as patient outcomes. It is quick, simple, and easy to use by Doctors, Nurses and Paramedics of all skill levels. Through collaboration with industry experts, key opinion leaders, engineers and Emergency Care based clinicians, who identified the unmet clinical need, ViVO has successfully developed a functional prototype to TRL 6.

As a direct result of this project, Pupiloscope forecasts sales of €20 Million within 5 years of product launch, improving patient outcomes and reducing both the societal and costs of care in the EU and Globally by an estimated €2 Billion per annum.

This project will seek to develop Pupiloscope into a clinically proven, manufacturing ready and CE approved medical device; incorporating technology finalisation, regulatory approval, health economics, clinical testing and validation, therefore enabling product launch and sales to the EU and Global Emergency Care healthcare markets.

Campo scientifico

Parole chiave

Programma(i)

Argomento(i)

EIC-SMEInst-2018-2020 - SME instrument

Invito a presentare proposte

H2020-EIC-SMEInst-2018-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-SMEInst-2018-2020-2

Meccanismo di finanziamento

SME-2 - SME instrument phase 2

Coordinatore

VIVO SMART MEDICAL DEVICES LTD

Contribution nette de l'UE

€ 875 637,88

Indirizzo

6 EDISON VILLAGE NOTTINGHAM SCIENCE TECHNOLOGY PARK
NG7 2RF Nottingham
Regno Unito

PMI

Sì

Regione

East Midlands (England) Derbyshire and Nottinghamshire Nottingham

Tipo di attività

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Collegamenti

Contatta l’organizzazione

Partecipazione a programmi di R&I dell'UE

Rete di collaborazione HORIZON

Costo totale

€ 1 250 911,25